Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Pfizer Stock Slips After Beat-And-Raise Quarter: What to Know

Pfizer reported a notable year-over-year decline in Q2 earnings, but the results still beat expectations. Here's what investors should know.

Nasdaq Dives As Two Dow Jones Leaders Crater; Tesla Falls As Microsoft Earnings Loom (Live Coverage)

Nasdaq Dives As Two Dow Jones Leaders Crater; Tesla Falls As Microsoft Earnings Loom (Live Coverage)

Stocks fell Tuesday as the Fed meeting got underway. Microsoft fell ahead of earnings while Merck and Proctor & Gamble plunged after results.

Investors Business Daily

Dow Jones Rises As Fed Meeting Kicks Off; Microsoft Earnings Next

Dow Jones Rises As Fed Meeting Kicks Off; Microsoft Earnings Next

The Dow Jones rose Tuesday, as the Federal Reserve's meeting kicks off. Microsoft earnings are up next on the stock market today.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Pfizer Stock Tops Its Buy Zone On Strong Earnings, Guidance Boost

Pfizer stock reversed higher Tuesday on a raised outlook for the year, driven by strong sales of heart and cancer drugs.

Investors Business Daily

S&P Futures Tick Higher Ahead of FOMC Meeting, U.S. JOLTs Report and Microsoft Earnings in Focus

September S&P 500 E-Mini futures (ESU24) are trending up +0.17% this morning as market participants braced for the start of the Federal Reserve’s two-day policy meeting while also awaiting the latest reading on U.S. job openings as well as an earnings report from tech giant Microsoft.

1 High-Yield Dividend Stock to Buy and Hold

Pfizer's stock shows signs of a potential rebound, buoyed by recent pipeline successes in hemophilia and obesity treatments, an attractive 5% dividend yield, and a rock-bottom valuation. This makes it an appealing dividend stock for value and income investors as the drug giant prepares to report earnings.

Option Volatility And Earnings Report For July 29 – August 2

This week we have Apple, Advanced Micro Devices, Amazon, Pfizer, Coinbase, Meta Platforms, Intel, Exxon Mobil, Boeing, PayPal, Starbucks, McDonald’s and Chevron all set to report.

inkl

Read news from The Economist, FT, and more,
with one subscription

Bird flu isn’t spreading in humans for now. But there are vaccines in the pipeline if that changes

Bird flu isn’t spreading in humans for now. But there are vaccines in the pipeline if that changes

Since May, a number of poultry farms around Australia have faced outbreaks of avian influenza, or bird flu. These outbreaks have been devastating for the poultry farms affected, necessitating large-scale culls, and have caused knock-on effects for the country’s egg supplies.

The Conversation

Ceos Condemn Political Violence After Trump Shooting

Ceos Condemn Political Violence After Trump Shooting

170 major CEOs unite to denounce political violence after Trump shooting, emphasizing peace and unity.

Here's What to Expect From Pfizer’s Next Earnings Report

Here's What to Expect From Pfizer’s Next Earnings Report

As Pfizer gears up to release its second-quarter earnings this month, analysts project a double-digit bottom-line dip.

1 Big Pharma Dividend Stock to Snag While It's Still Cheap

1 Big Pharma Dividend Stock to Snag While It's Still Cheap

Pfizer's stock presents a compelling investment opportunity, trading at an attractive valuation with a high dividend yield, as the company makes promising progress on its oral obesity drug, danuglipron, in a market dominated by injectable treatments.

Pfizer to move daily weight-loss pill to clinical trials

Firm says drug Danuglipron has shown ‘encouraging’ signs in early studies

Evening Standard

Pfizer Stock Jumps After Picking Daily Pill As Weight-Loss Drug

Pfizer Stock Jumps After Picking Daily Pill As Weight-Loss Drug

Pfizer stock jumped early Thursday after the drugmaker said it selected a once-daily pill to move forward as a potential weight-loss drug.

Investors Business Daily

Premarket Stocks: 3 Fast Movers And 1 In A Buy Zone

Premarket Stocks: 3 Fast Movers And 1 In A Buy Zone

Several stocks angled higher early Thursday with one in a buy zone and two looking to reclaim key levels.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Pfizer stock leaps on obesity drug challenge to Ozempic, Zepbound

Pfizer is looking to challenge leaders Eli Lilly and Novo Nordisk in the fast-growing market for weight loss drugs.

3 Value Stocks to Buy and Hold for Passive Income

Amid market volatility, three value stocks - American International Group (AIG), Pfizer (PFE), and Schlumberger (SLB) - emerge as potential long-term investments for passive income, offering attractive valuations, solid dividends, and growth prospects for investors.

The Independent UK

Vaccine panel more strongly endorses RSV shots for oldest Americans

Federal advisers are making a stronger endorsement for RSV vaccinations for people 75 and older

Investors Business Daily

Moderna Dives 11% After RSV Vaccine Proves Less Effective Than Pfizer, GSK Shots

Moderna stock tumbled Wednesday after the company said its newly approved RSV vaccine was only about 50% effective after 18 months.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Future of Weight-Loss Drugs for Investors

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

International Business Times

EU Chief's Texts For Covid Vaccines Under Court Scrutiny

A Belgian court on Friday heard a lawsuit accusing European Commission chief Ursula von der Leyen of secretly negotiating Covid vaccine purchases via text message and arguing she should be barred from a second term.

Investors Business Daily

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy more than tenfold, according to one estimate.

3 Ultra High-Yield Dividend Stocks to Pounce On at Every Dip

These dividend stocks have consistently paid dividends with yields over 6%.

New RSV shots tied to rare nervous system disorder — should you worry?

There's been some reports of Guillain-Barré syndrome in older adults who got the vaccines. But health officials still recommend that this population get the shots, in consultation with their doctors.

Investors Business Daily

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test

Sarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.

3 Healthcare Stocks With The Highest Yields As of June 2024

Looking for yield? Here's 3 healthcare stocks with the highest yields today.

1 … 4 5 6 7

People

Ursula von der Leyen

Joseph Schwartz

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

European Commission

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

243,837 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play